Menu
US
alphalisa technology 1920
Application Note

Immunogenicity assessment using the AlphaLISA technology

Biological drug products often elicit an immune response in patients that can lead to clinical consequences of the presence of anti-drug antibodies (ADA) varying from mild to serious adverse events. Therefore, the presence of ADA is a major safety and efficacy concern and should be evaluated and correlated with any pharmacological or toxicological observations.

The development of rapid and sensitive assay platforms for ADA detection is an essential step of the drug development process. In this application note, we demonstrate that the AlphaLISA mix-and-read homogeneous assay permits the sensitive detection of ADA.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Immunogenicity assessment using the AlphaLISA technology

Download Application Note